Quick definition: China’s Volume-Based Procurement (VBP) program (带量采购, dàiliàng càigòu) has driven drug prices down by an average of 53% across nine national rounds since 2018, covering more than 374 molecules. In contrast, free market pricing (自由市场定价, zìyóu shìchăng dìngjià) — the traditional route where manufacturers set prices without government volume guarantees — continues to deliver margins that can be 2 to 5 times higher, but with no guaranteed purchasing commitment. For foreign pharma executives, the core choice is which path to prioritize for each product in their portfolio, balancing sure volume against pricing power and long-term brand positioning in China’s $140 billion pharmaceutical market.
Why This Matters to Your China Market Entry
China’s pharmaceutical market is projected to exceed US$ 140 billion by 2025 (IQVIA Market Prognosis 2024), but access is no longer a simple matter of registration and launch. The National Healthcare Security Administration (NHSA) now mandates that hospitals meet purchasing quotas for centrally procured drugs, making VBP the default channel for many generics and even some innovative medicines. Meanwhile, free market pricing remains the only viable route for drugs not included in procurement lists, such as first-in-class biologics and rare-disease treatments. Misjudging which strategy fits your drug can delay launch by 12–18 months or lock you into a price that erases R&D returns.
The stakes are especially high for foreign pharmaceutical companies. Between 2020 and 2024, foreign-invested enterprises (FIEs) saw their aggregate China market share in VBP-affected categories decline from 38% to 22%, according to NHSA procurement data. Companies that embraced VBP with a structured strategy — like AstraZeneca and Novartis — maintained or grew their market presence. Those that resisted, like certain premium-brand European firms, lost 40–60% of their hospital access within 12 months of VBP implementation.
VBP vs Free Market Pricing: Side-by-Side Comparison
1. Pricing Dynamics and Margin Structure
- VBP route: Average price reduction of 53% vs pre-VBP levels, with individual price cuts ranging from 30% to 93% depending on competition intensity. Gross margins drop to 10–20% for winning bidders. However, the NHSA guarantees 70–80% of the hospital procurement quota for the contracted period (typically 12–24 months).
- Free market route: Manufacturers maintain pricing power with 30–60% gross margins, but face annual price erosion of 0–10% from competitive pressure. No volume guarantee — hospitals independently choose which products to stock and prescribe. Success depends on hospital-by-hospital listing negotiations, physician detailing, and brand loyalty.
- The margin-volume tradeoff: A typical VBP product with a 53% price cut and 4x volume increase generates 88% of pre-VBP revenue but only 30–40% of pre-VBP gross profit (assuming 50% COGS ratio). Free market products maintain higher absolute profit despite lower volume.
2. Market Access Speed and Coverage
- VBP route: Winning a VBP bid guarantees automatic listing on provincial procurement platforms within 3–6 months. Hospital coverage expands rapidly — winning bidders typically gain access to 2,000–5,000 hospitals within the first year, including lower-tier facilities they could not previously reach.
- Free market route: Requires 12–18 months of hospital-by-hospital listing negotiations after NMPA approval. Coverage is concentrated in top-tier tertiary hospitals (1,500–2,000 facilities nationally) with limited penetration of secondary hospitals and rural clinics.
- Coverage disparity: A 2024 McKinsey analysis found that VBP-enrolled drugs reached 82% of Chinese public hospitals within 18 months of contract award, compared to 23% for non-VBP drugs in the same therapeutic category.
3. Portfolio Strategy Implications
- VBP route: Best suited for mature, off-patent products with established manufacturing scale. Requires the ability to sustain margins at 10–20% gross margin. Volume growth of 200–400% offsets price cuts but demands supply chain capacity expansion.
- Free market route: Ideal for innovative, patent-protected products, first-in-class biologics, and drugs requiring specialized physician education. Margin preservation enables continued investment in R&D and medical affairs. Limited to 10–23% hospital penetration.
- Best practice: Leading foreign pharma companies now run dual portfolios — assigning mature products to VBP while reserving innovation assets for free market channels. AstraZeneca’s China strategy exemplifies this: its VBP portfolio grew volume by 340% while its innovation portfolio grew revenue by 22% CAGR between 2021 and 2024.
4. Regulatory and Compliance Burden
- VBP route: Requires compliance with NHSA procurement rules, including: (a) guaranteed supply at contracted prices, (b) quality consistency verification through NMPA’s一致性评价 (Consistency Evaluation) program, (c) real-time production data reporting to provincial procurement platforms. Non-compliance can result in blacklisting from future VBP rounds.
- Free market route: Requires standard NMPA market authorization plus hospital formulary listing, provincial tender participation (for public hospitals), and pricing compliance with 国家发改委 (NDRC) drug pricing guidelines. Administrative burden is lower but less predictable.
- Risk comparison: VBP carries higher regulatory stakes — non-compliance with supply obligations can trigger penalties of RMB 50,000–200,000 and temporary suspension from public procurement platforms. Free market violations typically result in smaller fines but slower corrective action.
5. Long-Term Strategic Positioning
- VBP route: Positions the company as a reliable, low-cost supplier to China’s public health system. Builds relationships with provincial health authorities and hospital pharmacy directors. Creates a foundation for launching follow-on products to the same customer base.
- Free market route: Preserves brand premium and pricing power. Enables investment in physician education, patient support programs, and clinical evidence generation. Maintains flexibility to exit China market if conditions change.
- Forward-looking: The NHSA has signaled expansion of VBP to biologics, biosimilars, and certain innovative drugs by 2027–2028. Companies relying solely on free market pricing for high-value products may find their strategy disrupted in the medium term.
Decision Data Table
| Parameter | VBP Route | Free Market Route |
|---|---|---|
| Average price reduction | 30–93% (avg 53%) | 0–10% annual erosion |
| Gross margin range | 10–20% | 30–60% |
| Volume guarantee | 70–80% procurement quota | None |
| Time to hospital access | 3–6 months | 12–18 months |
| Hospital coverage (18 months) | ~82% of public hospitals | ~23% of public hospitals |
| Revenue impact vs pre-VBP | 88% of pre-VBP revenue (avg) | 100%+ (no forced cut) |
| Gross profit impact vs pre-VBP | 30–40% of pre-VBP profit | 85–100% (market dependent) |
| Supply chain requirement | High volume, low cost capacity | Flexible, lower volume |
| Regulatory compliance scope | NHSA + NMPA + Consistency Eval | Standard NMPA + provincial |
| Suitable product lifecycle | Mature, off-patent, high volume | Innovation, patent-protected |
| Typical success metric | Volume growth 200–400% | Margin preservation + brand equity |
Cost Scenario Analysis
To illustrate the financial implications, consider a foreign pharmaceutical company with a mature hypertension drug generating $50M annual China revenue at 55% gross margin before VBP:
Scenario A — VBP Participation: Price cut of 53%, volume increase of 300%, COGS reduction of 30% through localization. Post-VBP revenue: $35.3M (70.5% of pre-VBP). Post-VBP gross profit: $12.7M (46% of pre-VBP). Profitability recovers to 65% of pre-VBP levels within 24 months as cost optimization matures.
Scenario B — Free Market Continuation: No price cut, 10% annual volume erosion from generic competition. Revenue after 2 years: $45M. Gross profit: $24.8M (90% of pre-VBP). Maintains higher profit but loses market share to VBP-enrolled competitors.
Scenario C — Hybrid Approach: Assign the drug to VBP in provinces where generic competition is intense, maintain free market pricing in provinces where brand loyalty is high. Revenue: $38M (VBP) + $18M (free market) = $56M total. Gross profit: $22.4M (81% of pre-VBP). This scenario requires separate pricing and supply chains for VBP vs non-VBP provinces.
Pitfalls to Avoid
Pitfall #1: Entering VBP without a cost localization plan. The most common mistake foreign pharma companies make is winning a VBP bid at an aggressive price without having a parallel plan to reduce cost of goods sold. If your manufacturing is overseas and your API is imported, a 53% price cut can turn a 55% gross margin product into a loss-making one. Always model your COGS at 40–50% of current levels before bidding, and have a concrete localization roadmap (domestic API sourcing, local fill-finish, optimized logistics) ready to execute within 90 days of contract award.
Pitfall #2: Assuming VBP participation is a one-time decision. VBP rounds are recurring — the NHSA typically re-bids each drug category every 12–24 months. Winning a VBP contract in Round 1 with an aggressive price does not guarantee renewal in Round 2. Competitors who lost the first round will return with even lower bids. Foreign companies must model a multi-round pricing trajectory: assume your winning price will need to drop an additional 15–30% at each successive bid round. If the resulting margin profile is unsustainable, consider exiting VBP after Round 1 and pivoting to a differentiated product.
Pitfall #3: Cannibalizing your own innovation pipeline. Several foreign pharma companies have made the strategic error of putting an innovative product into VBP too early in its lifecycle — accepting a 50%+ price cut on a drug with 3+ years of patent life remaining. While this generates volume, it destroys the product’s premium positioning and makes it nearly impossible to restore pricing later. Reserve VBP for drugs with less than 2 years of patent life or those already facing multiple generic competitors. Innovation assets with strong differentiation should remain in the free market channel to preserve their premium franchise.
Which Strategy Should You Choose?
- Choose VBP if: Your product is off-patent with multiple generic competitors, you have manufacturing scale or a localization roadmap to achieve low COGS, you can sustain gross margins at 10–20% and profit through volume, and your goal is to maximize hospital coverage and market share. Plan to invest in cost optimization within 90 days of contract award and model for multi-round price erosion of 15–30% per round.
- Choose free market pricing if: Your product has 2+ years of patent life, strong brand differentiation, or first-in-class status; your target market is private hospitals or self-pay channels; or your product is a biologic/biosimilar not yet included in VBP scope. Invest in physician education, clinical evidence generation, and patient support programs to justify the premium price.
- Choose a hybrid/dual-portfolio strategy if: You have both mature and innovative products in the same therapeutic category. Assign off-patent products to VBP to maintain hospital relationships, while reserving innovation assets for the free market. Manage the two channels with separate brand names or SKUs to avoid cannibalization. Monitor VBP scope expansion — biologics, biosimilars, and certain innovative drugs are expected to enter VBP by 2027–2028.
Remote China market entry support, built around execution.
